Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript Summary
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript Summary
Adjusted EBITDA loss reduced by 50% YoY in Q3.The following is a summary of the Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript:
以下是Standard BioTools Inc.（LAB）2024年第三季度业绩会交易摘要：
Financial Performance:
金融业绩：
Q3 revenue was $45 million, a 5% decrease YoY; non-GAAP gross margin increased to 57%.
Adjusted EBITDA loss reduced by 50% YoY in Q3.
第三季度营业收入为4500万美元，同比下降5％；非通用会计原则毛利率提高至57％。
第三季度调整后的EBITDA亏损同比减少50％。
Business Progress:
业务进展：
Achieved significant integration progress with SomaLogic, expecting $80 million savings in synergies by 2025.
Launched single SOMAmer agents, expanding protein identification services.
与SomaLogic取得重大整合进展，预计到2025年通过协同效应节省8000万美元。
推出单一SOMAmer代理，拓展蛋白质鉴定服务。
Opportunity:
机会：
Expansion plans with Illumina's platforms could broaden market for SomaScan technology.
Positioned to use strong cash position for future growth and operational scaling.
通过与illumina的平台合作，能够拓展SomaScan技术的市场。
凭借雄厚的现金储备，定位于未来增长和运营规模的利用。
Risk:
风险：
Revenue decline in instrument sales due to capital spending constraints and challenges in China.
Dependence on large contracts introduces revenue volatility.
仪器销售收入下降，原因是受到资本支出限制和中国市场挑战的影响。
对大型合同的依赖引入了营业收入的波动性。
Financial Performance:
金融业绩：
Q3 revenue totaled $45 million, down 5% year-over-year.
Year-to-date revenue at $128 million, showing a 9% drop compared to previous year.
Q3 non-GAAP gross margin improved to 57%, up from 52% year-over-year.
Non-GAAP operating expenses fell 24% year-over-year in Q3, demonstrating effective cost control.
Adjusted EBITDA showed a substantial reduction in loss by 50% year-over-year in Q3.
第三季度的营业收入总额为4500万美元，同比下降5%。
年至今的营业收入为12800万美元，与去年同期相比下降了9%。
Q3非GAAP毛利率改善至57%，同比提高了5个百分点，高于去年的52%。
非GAAP营业费用在Q3同比下降24%，展示了有效的成本控制。
调整后的EBITDA在Q3同比减少50%，显示出亏损显著降低。
Business Progress:
业务进展：
Significant progress in SomaLogic integration, achieving a full year ahead in cost reduction, totaling $80 million in synergies expected to be fully realized by 2025.
Focus on expanding service offerings, particularly SomaScan, which saw double-digit growth outside top five customers.
Highlighted the rollout of the SomaScan assay on Illumina's installed base projected for the first half of 2025.
Launched single SOMAmer agents as a product, expanding protein identification services.
Targeting adjusted EBITDA break even by the full year 2026 while pursuing long-term profitability.
在SomaLogic整合方面取得重大进展，实现了成本降低提前一年完成，预计到2025年将实现总计8,000万美元的协同效应。
专注于拓展服务业务，特别是SomaScan，在前五大客户以外实现了两位数的增长。
强调计划在2025年上半年就在illumina的已装机底下推出SomaScan测定。
推出单一SOMAmer代理作为产品，拓展蛋白质鉴定服务。
计划到2026年整体实现调整后的EBITDA达到盈亏平衡，同时追求长期盈利能力。
Opportunities:
机会：
Continues to expand and diversify customer base beyond major SomaScan clients, leading to revenue growth in lab services from new users.
Advanced plans for significant expansion through integration with Illumina's platforms, broadening market reach for the SomaScan technology.
Positioned to leverage strong cash and investment position to drive future growth and operational scaling.
继续扩大和多样化客户群，超越主要SomaScan客户，从新用户中实现实验室服务的营业收入增长。
通过与illumina平台整合，计划大规模扩展，拓宽SomaScan技术的市场覆盖范围。
凭借强大的现金与投资状况，有望推动未来增长和业务规模化。
Risks:
风险：
Revenue from instruments dropped significantly, particularly due to external capital spending constraints and market challenges in China, leading to delayed sales and elongated cycles.
Dependence on large contracts can lead to revenue volatility, as seen with the quarter-to-quarter variations influenced by client project timing and execution.
仪器营业收入显著下降，主要是由于中国市场的外部资本支出限制和市场挑战导致销售延迟和周期拉长。
依赖于大型合同可能导致营收波动，正如季度营收波动受到客户项目计时和执行的影响一样。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。
